Low-Cost Generic Drugs Under The President’s Emergency Plan For AIDS Relief Drove Down Treatment Cost; More Are Needed-Reference-Cited by-同舟云学术

Low-Cost Generic Drugs Under The President’s Emergency Plan For AIDS Relief Drove Down Treatment Cost; More Are Needed

Published:2012-07 Issue:7 Volume:31 Page:1429-1438
ISSN:0278-2715
Container-title:Health Affairs
language:en
Short-container-title:Health Affairs

Author:

Venkatesh Kartik K.¹,Mayer Kenneth H.²,Carpenter Charles C.J.³

Affiliation:

1. Kartik K. Venkatesh ( ) is a medical student at the Alpert Medical School, Brown University, in Providence, Rhode Island.

2. Kenneth H. Mayer is the director of HIV prevention research at Beth Israel Deaconess Medical Center and medical research director of Fenway Health, in Boston, Massachusetts.

3. Charles C.J. Carpenter is a professor of medicine at the Alpert Medical School, Brown University.

Publisher

Health Affairs (Project Hope)

Subject

Health Policy

Reference36 articles.

1. US Senate passes new PEPFAR bill

2. The President's Emergency Plan for AIDS Relief in Africa: An Evaluation of Outcomes

3. Generic antiretroviral drugs—will they be the answer to HIV in the developing world?

4. Use of Generic Antiretroviral Agents and Cost Savings in PEPFAR Treatment Programs

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Market Failure, State Failure: The Political Economy of Supply Chain Strengthening to Ensure Equitable Access to Vaccines and Medicines in Low- and Middle-Income Countries;Journal of Health Politics, Policy and Law;2023-07-31

2. The Social, Behavioral, and Ethical Modalities of COVID-19 on HIV Care in South Africa: A Systematic Review;International Journal of Environmental Research and Public Health;2022-08-08

3. An Evaluation of US Food and Drug Administration’s Program to Register HIV Drugs for Use in Resource-Constrained Settings;JAMA Network Open;2019-11-20

4. The influence of constraints on the efficient allocation of resources for HIV prevention;AIDS;2019-06-01

5. Impact of the US Food and Drug Administration registration of antiretroviral drugs on global access to HIV treatment;BMJ Global Health;2018-05